Gender differences in treatment with antidepressants during first weeks of a sick-leave spell due to depressive episode.
Journal
European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
pubmed:
29
9
2019
medline:
25
6
2021
entrez:
29
9
2019
Statut:
ppublish
Résumé
The incidence of depression is higher in women; women are more often on sick leave due to depression, and more women than men use antidepressants. The objective of this study was to explore possible gender differences in buying prescribed antidepressants during the first 21 days of a new sick-leave spell due to depressive episode. Included were all individuals living in Sweden in working age (18-64 years old) who in 2010 or 2011 began a new sick-leave spell due to depressive episode (ICD-10 F32) lasting at least 21 days (n = 44 863). Register data on sociodemographics, morbidity and dispensed prescription medication were used to investigate associations between gender and buying prescribed antidepressants in the total group and in subgroups, using multiple logistic regression models. The study population consisted of 69.5% women. Within the first 21 days of the sick-leave spell, 48.0% of the men and 42.1% of the women had dispensed prescribed antidepressants. In the adjusted multiple logistic regression model, men had an odds ratio of 1.28 (95% confidence interval 1.23-1.33) as compared with women, for buying prescribed antidepressants. In this nationwide register study, nearly half of the women and men on sick leave with depressive episode bought prescribed antidepressants during the first three weeks of the sick-leave spell. In the adjusted models, men were more likely to do this. Further studies are needed to elucidate the reasons for this gender difference.
Sections du résumé
BACKGROUND
The incidence of depression is higher in women; women are more often on sick leave due to depression, and more women than men use antidepressants. The objective of this study was to explore possible gender differences in buying prescribed antidepressants during the first 21 days of a new sick-leave spell due to depressive episode.
METHODS
Included were all individuals living in Sweden in working age (18-64 years old) who in 2010 or 2011 began a new sick-leave spell due to depressive episode (ICD-10 F32) lasting at least 21 days (n = 44 863). Register data on sociodemographics, morbidity and dispensed prescription medication were used to investigate associations between gender and buying prescribed antidepressants in the total group and in subgroups, using multiple logistic regression models.
RESULTS
The study population consisted of 69.5% women. Within the first 21 days of the sick-leave spell, 48.0% of the men and 42.1% of the women had dispensed prescribed antidepressants. In the adjusted multiple logistic regression model, men had an odds ratio of 1.28 (95% confidence interval 1.23-1.33) as compared with women, for buying prescribed antidepressants.
CONCLUSIONS
In this nationwide register study, nearly half of the women and men on sick leave with depressive episode bought prescribed antidepressants during the first three weeks of the sick-leave spell. In the adjusted models, men were more likely to do this. Further studies are needed to elucidate the reasons for this gender difference.
Identifiants
pubmed: 31562519
pii: 5575245
doi: 10.1093/eurpub/ckz172
pmc: PMC7183359
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-304Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association.
Références
J Public Health (Oxf). 2008 Mar;30(1):111-3
pubmed: 17981887
Am J Psychiatry. 1994 Jul;151(7):979-86
pubmed: 8010383
Lancet Psychiatry. 2017 Feb;4(2):146-158
pubmed: 27856392
Br J Psychiatry. 2005 Dec;187:495-6
pubmed: 16319399
Arch Gen Psychiatry. 2005 Jun;62(6):603-13
pubmed: 15939838
Lancet. 2012 Mar 17;379(9820):1056-67
pubmed: 22305766
Psychol Bull. 2017 Aug;143(8):783-822
pubmed: 28447828
J Clin Psychopharmacol. 2005 Aug;25(4):318-24
pubmed: 16012273
J Affect Disord. 2013 May;147(1-3):94-100
pubmed: 23167975
BMC Public Health. 2013 Jul 18;13:670
pubmed: 23866784
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Ger Med Sci. 2016 Feb 15;14:Doc02
pubmed: 26941590
BMJ Open. 2013 May 03;3(5):
pubmed: 23645921
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Can J Public Health. 2019 Oct;110(5):584-594
pubmed: 31089982
BJPsych Bull. 2017 Jun;41(3):145-150
pubmed: 28584650
Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1101-10
pubmed: 19688727
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
Am J Psychiatry. 2000 Sep;157(9):1445-52
pubmed: 10964861
Eur J Public Health. 2014 Aug;24(4):656-62
pubmed: 24903105
Psychol Med. 2003 Nov;33(8):1473-7
pubmed: 14672256
J Clin Psychiatry. 2013 Jun;74(6):595-602
pubmed: 23842011
BMC Psychiatry. 2016 Jan 15;16:4
pubmed: 26768890
Eur J Public Health. 2013 Aug;23(4):635-42
pubmed: 23302765
Psychiatr Serv. 2013 Oct;64(10):981-9
pubmed: 23820725
Scand J Public Health Suppl. 2004;63:49-108
pubmed: 15513654